Methodology
GLP-1 Ledger republishes public government records: mainly FDA’s, plus state board of pharmacy files and Justice Department and state attorney general press releases. Every row links to the document it came from, and nothing is estimated, rated or filled in. The records were last pulled on Nov 15, 2026 and are refreshed weekly.
Sources
- FDA warning letters: 155 letters. Found with FDA’s own full-text search for semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide, “GLP-1”, “compounded semaglutide” and “research use only semaglutide”. Each letter’s page on fda.gov is then read to record which GLP-1 ingredients it names (semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide, survodutide, mazdutide, dulaglutide, exenatide, orforglipron), whether it uses the word “compounded”, and whether it quotes research-use or not-for-human-consumption labeling.
- openFDA drug recall enforcement reports: 81 reports whose product description or recall reason names a tracked drug.
- FDA Registered Outsourcing Facilities: 100 facilities, FDA content current as of Nov 6, 2026. FDA publishes this as a table on the page, not a downloadable file. Contact names and phone numbers are not copied.
- FDA: Compounding: Inspections, Recalls, and other Actions: 399 503A and 503B facility entries with 1292 dated actions, FDA content current as of Oct 22, 2026. FDA publishes this as an A to Z list on the page. Each line (Form 483, warning letter, close-out, FMD-145, untitled or referral letter) is kept with FDA’s wording, its date and the document FDA links; a plain record type is added from FDA’s words. Entries FDA marks only as cross references (“see …”) are folded into the main entry, whose dba names they repeat. The page covers actions from 2019 on.
- Website addresses in letters: each GLP-1 warning letter’s text on fda.gov is scanned for website addresses (141 letters name at least one). Government, email and social media hosts are dropped; everything else is shown as FDA wrote it.
- FDA Drug Shortages, read through openFDA’s drug shortages endpoint: 14 entries for the tracked drugs.
- FDA Adverse Event Reporting System (FAERS), through openFDA’s drug event endpoint, checked Nov 15, 2026 (openFDA data updated Oct 28, 2026): counts of reports listing semaglutide, tirzepatide, liraglutide. A report counts for a drug when any drug entry names it in the product name or active ingredient field, in any role the reporter gave it. Totals, seriousness flags, years and reaction terms are openFDA’s own counts for that search. A report is counted as naming a compounded product only when one drug entry in it names the drug and that same entry either uses the word “compounded”, “compounding” or “compound” in its product name or dosage text, or lists the drug together with cyanocobalamin, methylcobalamin, pyridoxine, glycine, levocarnitine, carnitine, niacinamide or vitamin B12 or B6 in one product name, a combination no FDA-approved product of these drugs contains. openFDA’s public data has no field that marks a product as compounded and leaves out the report narrative, so this finds only reports whose product text shows it. FDA’s own counts for compounded semaglutide and tirzepatide, from its full internal data, are higher. The rule is applied to each drug entry on its own, so a report that lists, for example, compounded metformin next to brand liraglutide does not count. The openFDA fields read on these reports are: actiondrug, activesubstance, drugadditional, drugadministrationroute, drugauthorizationnumb, drugbatchnumb, drugcharacterization, drugcumulativedosagenumb, drugcumulativedosageunit, drugdosageform, drugdosagetext, drugenddate, drugenddateformat, drugindication, drugintervaldosagedefinition, drugintervaldosageunitnumb, drugrecurreadministration, drugrecurrence, drugseparatedosagenumb, drugstartdate, drugstartdateformat, drugstructuredosagenumb, drugstructuredosageunit, drugtreatmentduration, drugtreatmentdurationunit, medicinalproduct, openfda; none of them marks a product as compounded. FAERS reports are unverified, can be duplicates and do not show cause; this index publishes no rates and no comparisons of risk.
- FDA Data Dashboard inspection classifications and published Form 483s, read Nov 15, 2026: 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026 were searched by name, 282 pharmacy pages matched, with 647 classified inspections and 601 published Form 483s for the matched sites. The dashboard has no documented download interface for these tables; they are read from the same public data service its own download buttons use, without logging in, a few queries a week.
- Shortage history: 17 dated events quoted from FDA’s declaratory orders of December 19, 2024 (tirzepatide) and February 21, 2025 (semaglutide) and from FDA’s GLP-1 compounding statement page, each re-checked word for word against the source every week (last check Nov 15, 2026: 17 of 17 found), plus the dated entries in FDA’s shortage data. FDA’s Drug Shortages Database page for each drug is read as a second check of its status. FDA’s historical shortage download, linked from that database, returned “not found” when tried on November 5, 2026, so earlier per-presentation history is not included.
- FDA’s and the Federal Register’s published statements on compounding these drugs: 17 dated statements from 8 source pages. Each statement is written from the source page, and every weekly run re-fetches the page and confirms a key phrase is still there. As of the last run, all were re-confirmed.
Justice Department and state attorney general records
The enforcement page lists 10 actions from official press releases: 1 from the Justice Department (justice.gov) and 9 from state attorneys general (Connecticut Attorney General, Alabama Attorney General). Each record keeps the release title and date, the action type in the release’s own words, and the release’s sentence naming the firm, quoted. Every weekly run re-reads each release and drops any record whose title, date or quoted sentence is no longer on the page. Lawsuits, charges, letters and investigative demands are labeled as allegations. A release counts only when it names semaglutide, tirzepatide, another GLP-1 drug or a GLP-1 brand name, and a firm (individuals named alone are not listed).
This index read every press release on justice.gov’s press release list dated Jan 1, 2026 to Nov 14, 2026 (18,139 releases read through the department’s public press release API) and found 9 releases naming semaglutide, tirzepatide, another GLP-1 drug or a GLP-1 brand name. justice.gov asks automated readers to wait 10 seconds between requests, and this index does. State attorney general releases were found by search and read on each office’s own site, so that list is not complete for every state.
A firm in these releases is shown on an existing company page only when the release states the same name (after the normalization above) or a website FDA named in a GLP-1 warning letter. Otherwise it gets its own page. Nothing is matched on a similar name.
Not read: Federal Trade Commission (ftc.gov cases and press releases), because the FTC website answered this index’s requests with an error page instead of the page requested, so FTC cases and press releases were not read; this index does not work around blocks (checked Nov 7, 2026); Justice Department press releases dated before January 1, 2026, because justice.gov’s release pages answer automated requests with a bot check, so releases are read only through the department’s press release API, which this index reads back to January 1, 2026; earlier releases found by search were not read (checked Nov 7, 2026); Ohio Attorney General, because the Ohio Attorney General’s website did not respond to this index’s requests (checked Nov 7, 2026).
Federal lawsuits (CourtListener)
Not loaded: the court records source could not be read on the last check. No lawsuit records are shown anywhere on this site until it is.
FDA import records (API supply)
The GLP-1 import records page reads two FDA import sources on accessdata.fda.gov, 30 seconds apart per request as the host’s robots.txt asks, last on Nov 15, 2026. First, Import Alert 66-80 (published Oct 9, 2026): its reason, guidance and charge are quoted verbatim, and its Green List is shown entry by entry as FDA prints it, with FDA’s redaction in place of each firm name. 12 drug import alerts (66-80, 66-41, 66-40, 66-66, 66-72, 66-78, 66-79, 66-57, 66-76, 54-16, 55-05, 99-34) are searched for the words semaglutide, tirzepatide, liraglutide, retatrutide and GLP-1; other alerts are not searched. Second, FDA’s Import Refusal Report bulk files (Jan 1, 2002 to Oct 30, 2026), plus FDA Data Dashboard rows not yet in a bulk file: a line is kept when FDA’s product code description names one of those words (717 lines). A line counts as an API or powder form only when its product code is one Import Alert 66-80 itself lists. Declared manufacturer names that do not read as a business (no legal suffix or business word, and not a listed brand manufacturer spelling) are dropped at ingest with their city and FEI, so private individuals are never named; their lines still count by date, country and product. 67 business names get a page, one per spelling and country as FDA wrote it. No page is made for brand-name drug makers entered as declared manufacturer (Eli Lilly, Novo Nordisk, AbbVie, AstraZeneca, Bristol-Myers Squibb, Elanco and other originators, by name), for names that stop at exactly 32 characters or end in a cut-off word (read as truncated in FDA’s file) or are mostly digits, or for business names that open with a personal first and last name (those names are not shown); all of these lines still count in the totals. A firm page links to a company page only on the exact normalized name, and to a pharmacy page only on the exact name (U.S. firms) or the same FEI number.
FDA NDC Directory listings
The NDC listings page reads FDA’s four NDC Directory download files from accessdata.fda.gov, 30 seconds apart, last on Nov 15, 2026: finished drugs, unfinished drugs, the compounded drugs file of outsourcing facility product reports, and the excluded drugs file of listings FDA removed or excluded. A row is kept when its substance, nonproprietary or proprietary name names semaglutide, tirzepatide, liraglutide, retatrutide or cagrilintide (467 listings); an excluded row with blank names is kept only when its application number is one a kept finished or unfinished listing carries. Fields, including the marketing category, are copied as FDA gives them; the compounded file’s package rows are grouped into one listing per product NDC. openFDA’s drug NDC endpoint is read for per-drug totals as a cross-check. FDA’s NDC Directory disclaimer is quoted verbatim and checked against FDA’s page on each run. A labeler is shown on a 503B facility, pharmacy, company or import records page only when its name, or a “dba” name in it, has the same normalized key as that page; the NDC files carry no FEI number or address, so no other match is made, and a firm with several locations shows the same listings on each. 26 labelers with 2 or more compounded or bulk ingredient listings and no other page get their own page; Novo Nordisk and Eli Lilly entities, approved-product labelers and further-processing labelers are listed without a page.
Medicare and Medicaid spending
The spending page reads two CMS sources, aggregate only: no prescriber, pharmacy or patient level file is read. First, CMS’s Medicare Part D Spending by Drug file (DSD_PTD_RY26_P04_V10_DY24_BGM.csv), 2020 to 2024, through the data.cms.gov data API, with requests spaced 10 seconds apart as that host’s robots.txt asks. Rows whose generic name contains “tide” are fetched and a row is kept only when CMS’s generic name is exactly one of Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Exenatide Microspheres, Lixisenatide, Insulin Glargine/Lixisenatide, Insulin Degludec/Liraglutide, using CMS’s “Overall” row for each brand. The Part B file is searched the same way for generic names containing glutide, xenatide, tirzepatide, lixisenatide, to record whether it has any GLP-1 row. CMS’s catalog sentences quoted on the pages are re-checked against data.cms.gov/data.json on each run.
Second, CMS’s Medicaid State Drug Utilization Data, one dataset per year from 2020 to 2026, through data.medicaid.gov’s datastore query API (product name starting with any of the names below, 8,000 rows a page, 5 seconds apart). CMS gives only the first 10 characters of the FDA listing name, so a row is kept when the first word of that name is exactly one of: OZEMPIC (Ozempic); WEGOVY (Wegovy); RYBELSUS (Rybelsus); SEMAGLUTID (Semaglutide (generic name listing)); MOUNJARO (Mounjaro); ZEPBOUND (Zepbound); TIRZEPATID (Tirzepatide (generic name listing)); VICTOZA (Victoza); SAXENDA (Saxenda); LIRAGLUTID (Liraglutide (generic name listing)); TRULICITY (Trulicity); TRULICITY0 (Trulicity); DULAGLUTID (Dulaglutide (generic name listing)); BYETTA (Byetta); BYDUREON (Bydureon); EXENATIDE (Exenatide (generic name listing)); ADLYXIN (Adlyxin); SOLIQUA (Soliqua); XULTOPHY (Xultophy). Rows are added up by state, year, quarter and product, fee-for-service and managed care together. A row CMS marks suppressed is counted as suppressed and its blank values are never treated as zero: a total that includes one is shown as “at least” the published sum, and a total of only suppressed rows is shown as “Suppressed.” National figures are the rows CMS files under the state code XX. As read on Nov 15, 2026: 2020, 5,073 rows (1,682 suppressed); 2021, 6,574 rows (2,143 suppressed); 2022, 8,243 rows (2,985 suppressed); 2023, 9,756 rows (3,101 suppressed); 2024, 10,631 rows (3,186 suppressed); 2025, 12,829 rows (4,096 suppressed); 2026, 3,454 rows (1,141 suppressed), quarters 1 posted.
Neither source nets out rebates, and neither says what a prescription was for. Retatrutide and cagrilintide are searched for in both; a drug page says a file has no product under a name only when that search ran.
How records are matched to companies
Company names are normalized (case, punctuation, suffixes such as Inc. and LLC, and anything after “dba”) and records are joined on that key. So “FitRX, LLC dba Zealthy” and “FitRX, LLC dba AM RX” appear on one company page, with every name FDA used listed there. A company page exists only when a warning letter or recall names a GLP-1 ingredient; being on FDA’s 503B list alone does not create one, because that list does not say what a facility makes.
Each facility on FDA’s 503B list has its own page. It is matched to its entry on FDA’s compounding actions page when both are 503B, in the same city and state, and their legal or dba names share the same normalized key or the same first distinctive word (for example “Olympia Pharmaceuticals” and “OPS International, Inc. (dba Olympia Pharmacy)”, both in Orlando, Florida). If two entries could match, none is shown. Company pages show compounding action entries whose legal or dba name has the same normalized key as the company. Pages that gather records under a shared name, such as the Empower, Olympia and Strive question pages, say plainly that the records do not show how the named entities are related.
Each pharmacy page (under pharmacies by state) gathers the entries on FDA’s compounding actions page and the rows on FDA’s 503B list for one pharmacy. Records are merged only when a legal or dba name has the same normalized key and the city and state are the same (“St.” and “Saint”, “Mt.” and “Mount” count as one city). A name FDA gives as “formerly” is a different legal entity and is never used to merge. Records that come close but fail the rule, such as the looser first-word match used on the 503B facility pages, stay on separate pages and are listed on each as a close but not exact match. When FDA lists the same letter under a firm’s 503A and 503B entries, it is counted once. Every pharmacy answer uses one of four forms: record found, with the source and date; no matching record found in a named source on a date; not checked, with the reason; or no match possible, when FDA gives nothing to match on.
“Type” on a company page repeats a label in an FDA subject line (for example “(Telehealth)” or “(Internet Pharmacy)”) or the company’s presence on FDA’s 503B list. Subject groups on the letters page restate FDA’s subject line; FDA’s exact wording is always shown.
FDA inspection classifications
The FDA Data Dashboard identifies each inspected site by an FEI number, which neither FDA’s 503B list nor its compounding actions page prints. A dashboard site is tied to a pharmacy page only when its legal name has the same normalized key as one of the page’s FDA names and its city and state are the page’s. The site’s inspections are then read by its FEI number, keeping those listed under the matched name, and its published Form 483s by FEI number alone. A site with the same name and state in another city is shown on the page as close but not exact, never as its record. Each inspection shows FDA’s classification as the dashboard words it (No Action Indicated, Voluntary Action Indicated or Official Action Indicated) with its end date and project area. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, and FDA publishes only some Form 483s, so a missing inspection or 483 is reported only as not found in the dashboard on the date checked.
Form 483 observations
FDA publishes Form 483s (inspectional observations) as PDF links in three places this index reads: under each facility on its compounding inspections and actions page (some of those links point to an Internet Archive copy, which FDA itself links when it has removed the file), in the “Form 483 Issued?” column of its 503B list, and in the FDA Data Dashboard by FEI number. Every such link for a pharmacy or outsourcing facility with a page here is downloaded once (734 PDFs as of Nov 15, 2026), at least 30 seconds apart on fda.gov as its robots.txt asks.
A PDF is shown on a page only when its cover matches the page: the cover’s FEI number is one the FDA Data Dashboard ties to that page (see above), or the firm name on the cover (either side of a “dba”) has the same normalized key as one of the page’s names and the cover’s city and state are the page’s. Where FDA lists one firm under two entries that this index keeps on separate pages, a 483 that matches both is shown on both. The observations are read from the PDF’s text, in the order and with the numbers FDA printed. A 483 is skipped, and counted, when it or any of its pages has no text layer (a scanned image without one), when its observation numbers do not run 1, 2, 3 without a gap (a misread heading), when more than 2% of its words look like character-recognition noise, or when its cover matches no page. As of Nov 15, 2026: 476 shown, 39 with no readable text, 127 with observations that could not be read reliably, 80 matching no page, 1 not downloaded.
Text is quoted as extracted, with spacing tidied. FDA’s en and em dashes are written as hyphens, and FDA’s redaction markers (such as “(b)(4)” or “<Redacted B4>”) are kept. Some 483s are scanned images with a character-recognition text layer; those are marked on the page because that layer can misread characters. Names of people on the cover and in the signature box (the person the form was issued to and the investigators) are never stored, and any of those names, or a name after “Mr.”, “Ms.”, “Mrs.”, “Dr.” or “Miss”, found in an observation is replaced with “Name not shown”. Firm names and addresses are shown. The district office is the address printed in the form’s “District address” box, without phone numbers.
Themes on the 483 pages are counted with a fixed keyword table, printed on the answer page, applied only to each observation’s one-line lead statement. A 483 is not a final FDA determination, and a theme count is not a finding by this site.
State board records
For California, Colorado, Connecticut, Delaware, Florida, Illinois, Michigan and Texas, each pharmacy page is checked against the state board of pharmacy’s own public file. A board row is tied to a pharmacy only when a name on the row has the same normalized key as one of the pharmacy’s FDA names, and the row’s city and state are the pharmacy’s. A street address is never used to add or drop a match. Rows that come close (same name in another city, or a longer form of the name in the same city) are listed on the page as close but not exact, never as its license. Nonresident licenses another checked board issued count only when the board row names the pharmacy’s own city and state. When no row matches, the page says no license with that exact name and city was found in the file of that date, because a pharmacy can hold its license under a different legal name; that is not a finding that it is unlicensed. Board actions are quoted in the board’s words and are not characterized.
For Maryland, New York, Tennessee and Virginia, this index reads the board’s published disciplinary actions but not its license records, so the license answer on those pages says license records are not checked, with the reason. Each action is tied to a pharmacy page by the same rule: a name on the action has the same normalized key as one of the pharmacy’s FDA names, and the city and state given with the action are the pharmacy’s. An action that names another state’s address can only match a pharmacy page in that state, where it is shown as a board action in another state. When no action matches, the page says no action under that exact name and city was found in that list over the dates it covers.
- California State Board of Pharmacy: file dated Nov 6, 2026 (the date DCA last updated the file in its public information folder), 139,255 rows read, 7,356 pharmacy licenses kept. License types kept: Retail Pharmacy (PHY); Hospital Pharmacy (HSP); Resident Licensed Sterile Compounding (LSC); Non Resident Pharmacy (NRP); Non Resident Licensed Sterile Compounding (NSC); Outsourcing Facility (OSF); Nonresident Outsourcing Facility (NSF). Statuses in the file: Active, Delinquent, Inactive. 21 of 54 California pharmacy pages match a license, and 52 pharmacy pages in other states match a license that names its own city and state. Discipline: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. 1,014 actions, dated Jan 5, 2005 to Oct 28, 2026.
- Colorado State Board of Pharmacy: file dated Nov 15, 2026 (the date the Department of Regulatory Agencies last updated the dataset on data.colorado.gov), 6,166 rows read, 5,546 pharmacy licenses kept. License types kept: license type codes PDO, SPDO, TPDO, OSP, HSP as the dataset gives them (pharmacy outlets, including out-of-state pharmacies under OSP); codes for individuals and non-pharmacy outlets dropped. Statuses in the file: Active, Active - Restricted, Active - With Conditions, Cancelled, Expired, Revoked, Surrendered, Suspended, Voluntary Surrender. 6 of 14 Colorado pharmacy pages match a license, and 103 pharmacy pages in other states match a license that names its own city and state. Discipline: Discipline the Department of Regulatory Agencies publishes with each license in the dataset (case number, program action and effective date), worded as the department gives it. 1,425 actions, dated Oct 11, 1985 to Oct 30, 2026.
- Connecticut Department of Consumer Protection: file dated Nov 15, 2026 (the date the Department of Consumer Protection last updated the dataset on data.ct.gov), 5,121 rows read, 4,809 pharmacy licenses kept. License types kept: credential types PCY (PHARMACY) and PCN (NONRESIDENT PHARMACY); 312 rows whose status marks an application rather than an issued license (PENDING, DENIED, EXPIRED APPLICATION, APPROVED) dropped. Statuses in the file: ACTIVE (CURRENT), CLOSED, CLOSED (WITHDRAWN), INACTIVE, INACTIVE (BAD PAYMENT TRANSACTION), INACTIVE (DOES NOT WISH TO RENEW), INACTIVE (EXPIRED MORE THAN 3 YEARS - MUST REAPPLY), INACTIVE (REGISTRATION NOT REQUIRED), INACTIVE (REVOKED), INACTIVE (SURRENDERED), INACTIVE (WITHDRAWN), LAPSED. 2 of 8 Connecticut pharmacy pages match a license, and 104 pharmacy pages in other states match a license that names its own city and state. Discipline: The dataset gives each license’s status and status reason in the department’s words but lists no disciplinary actions, so Connecticut board actions are not checked.
- Delaware Division of Professional Regulation: file dated Nov 10, 2026 (the date the Division of Professional Regulation last updated the dataset on data.delaware.gov), 4,132 rows read, 4,120 pharmacy licenses kept. License types kept: Pharmacy profession license types Pharmacy - Retail, Pharmacy - Hospital, Temporary Pharmacy - Retail, Pharmacy-Military Provisional, Non Resident Pharmacy, Outsourcing Facility-Pharmacy, Outsourcing Facility-Distributor, as the dataset gives them (in-state and nonresident pharmacies and outsourcing facilities); pharmacists, interns, wholesalers, manufacturers and medical gas dispensers dropped, and 1 row naming a person. Statuses in the file: Active, Closed, Deactivated, Expired, Revoked, Terminated. No Delaware pharmacy has a page here; the file is read for nonresident licenses, and 119 pharmacy pages in other states match a license that names its own city and state. Discipline: Disciplinary actions the Division of Professional Regulation publishes in its Disciplinary Actions for Professional and Occupational Licensees dataset on data.delaware.gov (updated November 9, 2026), joined to the license by its number. The dataset gives the action and its start date only, worded as the division gives them, and links no documents. The license file’s own disciplinary action column reads N on 16 licenses that have an action in the discipline dataset, so that column is not used. 18 actions, dated Sep 3, 1980 to Mar 20, 2019.
- Florida Board of Pharmacy: file dated Nov 15, 2026 (the date this index ran the Florida Department of Health’s export, which is generated on request), 25,396 rows read, 25,396 pharmacy licenses kept. License types kept: Pharmacy (every permit the Board of Pharmacy issues under that profession; the export does not give the permit type). Statuses in the file: Clear, Closed, Deleted, Disc Relinquish, Error, Expired Appl, Null And Void, Obligations, Probation, Revoked, VR Pend Bd Act, Vol Relinquish, Withdrew. 37 of 48 Florida pharmacy pages match a license. Discipline: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. 2,136 actions, dated Sep 19, 1980 to Nov 10, 2026.
- Illinois Department of Financial and Professional Regulation: file dated Nov 13, 2026 (the date IDFPR last updated the dataset on data.illinois.gov), 16,780 rows read, 14,765 pharmacy licenses kept. License types kept: business licenses of type PHARMACY described as LICENSED PHARMACY, LICENSED DIVISION II PHARMACY, LICENSED DIVISION III PHARMACY, LICENSED DIVISION IV PHARMACY, LICENSED DIVISION V PHARMACY, LICENSED DIVISION VI PHARMACY, as the dataset gives them (in-state and nonresident pharmacies); pharmacists, technicians, controlled substance licenses and wholesale distributors dropped. Statuses in the file: ACTIVE, CANCELLED, CHANGE OF OWNERSHIP, CLOSED, EXPIRED, INOPERATIVE, NOT RENEWED, Non Sufficient Fund Check Terminated, PERMANENT INACTIVE, PROBATION, REFUSE TO RENEW, RELINQUISH, REVOKED, SUSPENDED, VOLUNTARY SURRENDER. 7 of 10 Illinois pharmacy pages match a license, and 121 pharmacy pages in other states match a license that names its own city and state. Discipline: Discipline IDFPR publishes with each license in the dataset (case number, action, start date and the department’s one-line reason), worded as the department gives it. The dataset marks 931 of these licenses as ever disciplined; some of them carry no action in the dataset. 1,250 actions, dated May 23, 1980 to Sep 10, 2026.
- Maryland Board of Pharmacy, read Nov 15, 2026 (the date this index read the board’s Formal Disciplinary Actions page and the orders it links): 2,109 entries read, 312 actions kept. Kept: permit holders (pharmacies, distributors and other businesses named in an order, or respondents holding a P or D permit who are not named as a person); orders against pharmacists and technicians dropped. 0 of 7 Maryland pharmacy pages match an action, and 5 pharmacy pages in other states match an action that names their own city and state. Discipline: Orders and notices the Maryland Board of Pharmacy links on its Formal Disciplinary Actions page, read from each PDF: 2,109 documents listed, of which 1,337 are labeled with a person’s surname and initials (orders against pharmacists and technicians) and were not read; of the other 772, 328 had readable text, 438 scanned without a text layer and 6 that could not be downloaded. 312 name a permit holder rather than a pharmacist or technician; for 98 of them no city could be read from the document, so they cannot be matched to a page. Each is dated by the date on the board’s list, and the title and passage are copied from the PDF’s text layer, which for scanned orders is a machine reading of the page and can misread a letter, so open the document before relying on a quoted word. Maryland pharmacy permits themselves are not checked. 16 documents have no readable title. Actions dated Jan 2, 2007 to Oct 20, 2026. License records not checked: the board’s license verification is an interactive search, which this index does not use.
- Michigan Department of Licensing and Regulatory Affairs: file dated Nov 10, 2026 (the date this index ran LARA’s Pharmacy license list, which its licensing system generates on request), 139,297 rows read, 3,461 pharmacy licenses kept. License types kept: license types Pharmacy and Remote Pharmacy in the Pharmacy group (in-state and out-of-state); pharmacists, technicians, interns, controlled substance licenses, manufacturers and wholesale distributors dropped. Statuses in the file: Active, Active - In Late Renewal, Disciplinary Limited. 1 of 4 Michigan pharmacy pages match a license, and 73 pharmacy pages in other states match a license that names its own city and state. Discipline: LARA’s list gives each license’s status in the department’s words but lists no disciplinary actions, and the department’s disciplinary action reports sit on its website, which refused this index’s automated requests, so Michigan board actions are not checked. The list covers active licenses only (including those the department marks as in late renewal or limited), so a pharmacy with no match may hold a license that is no longer active.
- New York State Education Department, read Nov 8, 2026 (the date this index read the Office of the Professions’ list, which the office updates as the Board of Regents acts): 2,661 entries read, 421 actions kept. Kept: pharmacy establishments (entries with a registration number whose profession is not pharmacist, technician or intern); entries for individual licensees dropped. 3 of 19 New York pharmacy pages match an action, and 1 pharmacy page in another state matches an action that names its own city and state. Discipline: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions dated Jan 14, 1994 to May 19, 2026. License records not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request.
- Tennessee Board of Pharmacy, read Nov 15, 2026 (the date this index read the Department of Health’s monthly reports): 1,755 entries read, 379 actions kept. Kept: business licensees in the Board of Pharmacy section (pharmacies, manufacturers, wholesalers); entries for pharmacists and technicians dropped. 2 of 15 Tennessee pharmacy pages match an action, and 1 pharmacy page in another state matches an action that names its own city and state. Discipline: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions dated January 2004 to April 2026. License records not checked: the Department of Health’s license verification site did not respond to this index’s requests.
- Texas State Board of Pharmacy: file dated Nov 15, 2026 (the file’s last-modified date on the board’s server), 8,615 rows read, 7,724 pharmacy licenses kept. License types kept: Community Pharmacy; Community Sterile Compounding; Institutional (Hospital); Institutional Sterile Compounding; Non-Resident (Not Located in Texas); Non Resident Sterile Compounding. Statuses in the file: Active, Delinquent, Expired Pharm, Probation, Revocation. 20 of 57 Texas pharmacy pages match a license, and 32 pharmacy pages in other states match a license that names its own city and state. Discipline: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online. License status checked; board disciplinary orders reported only as the file’s flag.
- Virginia Board of Pharmacy, read Nov 15, 2026 (the date this index read the Department of Health Professions’ list of case decisions from the last 90 days): 60 entries read, 89 actions kept. Kept: pharmacies and outsourcing facilities, resident and nonresident (occupations on the list: Business CSR, Non-resident Outsourcing Facility, Non-resident Pharmacy, Pharmacist, Pharmacy, Pharmacy Technician, Pharmacy Technician Trainee); pharmacists, technicians and business controlled substance registrations dropped. 0 of 9 Virginia pharmacy pages match an action, and 2 pharmacy pages in other states match an action that names their own city and state. Discipline: Board of Pharmacy case decisions the Department of Health Professions lists as entered in the last 90 days, worded as it gives them. Older decisions are reachable only through a search form, which this index does not use, so only that 90-day window is checked. The orders themselves sit behind a disclaimer form and are not linked. Virginia pharmacy licenses are not checked. Actions dated Aug 17, 2026 to Nov 15, 2026. License records not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use.
Not checked: Alabama, because the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search; Arizona, because the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks; Arkansas, because the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026; Georgia, because no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search; Idaho, because the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read; Indiana, because the Professional Licensing Agency sells its license files rather than publishing them, and its discipline records are behind an interactive search; Kansas, because the board’s website answers automated requests with a bot challenge, and this index does not work around blocks; Kentucky, because the board releases its license rosters only on request, and its board actions page shows nothing without running scripts; Louisiana, because no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search; Massachusetts, because the board’s website refused automated requests, and this index does not work around blocks; Minnesota, because the board’s website answers automated requests with a bot challenge, and this index does not work around blocks; Mississippi, because the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search; Missouri, because the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages; Nevada, because no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search; New Jersey, because the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks; North Carolina, because the board’s website refused automated requests with an access error, and this index does not work around blocks; Ohio, because the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks; Oklahoma, because no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search; Oregon, because the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search; Pennsylvania, because the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page; South Carolina, because the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026; Utah, because the Division of Professional Licensing’s website refused automated requests, and this index does not work around blocks; Washington, because the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use; Wisconsin, because the Department of Safety and Professional Services shows orders only through a script-driven search behind a user agreement, and its license lookup is an interactive search; Alaska, Hawaii, Maine, Montana, Nebraska, New Hampshire, Puerto Rico, Rhode Island, South Dakota, Vermont, West Virginia, because this index has not yet added those boards’ records. Florida’s export gives no state for nonresident permits, so Florida nonresident licenses held by pharmacies in other states are not checked. Texas license detail pages and California’s per-license detail pages are not fetched, because the boards’ robots.txt files disallow them. The New York Office of the Professions’ list pages and Tennessee’s monthly reports are fetched at most once a week, with past years kept longer, and both sites’ robots.txt files allow them. Illinois, Connecticut and Delaware licenses (and Delaware’s discipline) are read from the states’ open-data portals (data.illinois.gov, data.ct.gov and data.delaware.gov) through the portals’ published query endpoints, with a pause between requests as their robots.txt files ask. Michigan’s list is the Pharmacy group report that LARA’s licensing system generates as a spreadsheet, with no login, and that LARA’s License Lists and Reports page links; that page refused this index’s automated requests, so the report is opened directly, once a week, at https://aca-prod.accela.com/MILARA/Report/ShowReport.aspx?module=Licenses&reportID=32414&reportType=LINK_REPORT_LIST (the same report anyone can open from LARA’s page, without an account). The report host, aca-prod.accela.com, publishes no robots.txt file (checked November 11, 2026), so it sets no crawl limits. It lists active licenses only. Virginia’s list covers only case decisions entered in the last 90 days, so a Virginia pharmacy page with no matching action says so for that window only. Maryland’s Board of Pharmacy lists its orders by name and date and gives the city only inside each PDF, so every order not labeled with a person’s surname and initials is downloaded, about two seconds apart, and read; robots.txt on health.maryland.gov allows the order files. The city comes from the respondent’s address block or a sentence placing it (“located in Hagerstown, Maryland”). Orders whose PDF is a scan with no text, or whose text gives no city, cannot be matched and are not shown on any pharmacy page, because a name alone does not tie an order to a pharmacy. Boards looked at between Nov 6, 2026 and Nov 10, 2026 and not read: Alabama, Arkansas, Arizona, Georgia, Iowa, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Minnesota, Missouri, Mississippi, North Carolina, New Jersey, New Mexico, Nevada, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Utah, Washington and Wisconsin, for the reasons above, and, for states with no pharmacy page here, Iowa, because no license file was found on the board’s website when checked on November 10, 2026, and its license lookup and board action search are interactive searches; New Mexico, because the Regulation and Licensing Department lists Board of Pharmacy actions in a script-driven table, and its license verification is an interactive search.
What is excluded
- Letters that use GLP-1 wording but name no GLP-1 ingredient, such as dietary supplements marketed with “GLP-1” in the product name: 4 letters at the last run.
- Letters to companies that hold FDA approvals for these ingredients (for example about advertising of an approved product): 5 letters.
- Recalls of FDA-approved products, identified by brand name (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Xultophy, Soliqua) or by a firm that holds an approval for the ingredient: 9 reports.
- Prices, product reviews, ratings, and efficacy or safety claims of any kind (FAERS figures are shown only as counts of reports, with FDA’s caveats), and data from private verification programs (NABP, LegitScript). This site does not compare companies.
Limits
- FDA’s full-text search covers letters FDA has posted. FDA posts letters after it issues them, sometimes weeks later.
- Name matching can miss a company that appears under unrelated names, or that uses a website name in one record and a legal name in another.
- State board of pharmacy records outside the states listed under State board records, court records and other agencies are not included.
- FDA’s two compounding lists spell names differently, so the 503B list to actions page match can miss a facility FDA lists under an unrelated name.
Updates and corrections
The ingest runs weekly and replaces each data file only when its source downloads and validates. If a record here differs from the FDA original, the FDA original is correct; the fix is made at the next run.
Last run notes: 3 source issue(s) recorded; the previous data was kept for those sources.